Difficulty: Medium
Average Score: 83%
Practice
The following are licensed in the UK for the management of obesity:
Correct answer
A
Rationale
In the context of gastrointestinal drug management for obesity in the UK, understanding the correct medication is crucial for patient safety and effective treatment. Orlistat (option A) is the correct answer among the options provided. Orlistat is a lipase inhibitor that works by reducing the absorption of dietary fat in the intestines, leading to weight loss. It is licensed in the UK for the management of obesity and is recommended for use in conjunction with a reduced-calorie diet.
Sibutramine (option B) was previously used for weight loss but has been withdrawn from the market due to safety concerns regarding cardiovascular events. Thiazide diuretics (option C) are used for managing hypertension and edema, not for obesity. Pizotifen (option D) is an antihistamine medication used for preventing migraines and does not have a role in obesity management.
Educationally, it is important to highlight the mechanism of action and indications of each drug to enhance students' understanding of pharmacological treatments for obesity. Understanding the differences between these medications can prevent medication errors and promote evidence-based practice in the management of obesity. By clarifying the correct and incorrect options, students can develop a sound knowledge base for making informed decisions in clinical practice.
Sibutramine (option B) was previously used for weight loss but has been withdrawn from the market due to safety concerns regarding cardiovascular events. Thiazide diuretics (option C) are used for managing hypertension and edema, not for obesity. Pizotifen (option D) is an antihistamine medication used for preventing migraines and does not have a role in obesity management.
Educationally, it is important to highlight the mechanism of action and indications of each drug to enhance students' understanding of pharmacological treatments for obesity. Understanding the differences between these medications can prevent medication errors and promote evidence-based practice in the management of obesity. By clarifying the correct and incorrect options, students can develop a sound knowledge base for making informed decisions in clinical practice.